“Lebrikizumab Demonstrates Consistent Efficacy at 16 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis Regardless of Baseline Disease Severity”. SKIN The Journal of Cutaneous Medicine, vol. 7, no. 6, Nov. 2023, p. s274, https://doi.org/10.25251/skin.7.supp.274.